Serum Index for Malignant Pleural Effusion (SIMPLE): A non-invasive, blood-based prognostic score for patients with newly diagnosed and relapsing MPE.
SIMPLE shows promise as a prognostic tool for malignant pleural effusion, outperforming traditional scoring models, but requires external validation before clinical use.
Where it sits
this study against the rest of the humanin corpusSummary and findings
This study evaluated the prognostic value of a novel serum-based index (SIMPLE) for patients with malignant pleural effusion (MPE) compared to established scoring models. A total of 678 patients were included, and the study found that SIMPLE had a higher area under the curve (AUC) than the LENT and PROMISE scores. The findings suggest that SIMPLE may offer improved prognostic capabilities, but external validation is necessary.
Abstract
<h4>Background</h4>Accurate prognostication of malignant pleural effusion (MPE) is essential to guide management decisions and provide patients with meaningful survival estimates. LENT and PROMISE scores are widely recognised MPE-specific prognostic tools, although with limited uptake in clinical practice. More objective, serum-based indices such as the Prognostic Index for Cancer Outcomes (PICO) and Modified Glasgow Prognostic Score (mGPS) have shown robust prognostic value in oncology and may offer advantages by allowing reproducible, treatment-responsive reassessment.<h4>Methods</h4>Retrospective cohort study including patients with MPE, defined by cytological and/or histopathological confirmation, between 2012-2022 at a Portuguese tertiary hospital. Demographic, clinical and biochemical data were extracted from medical records, enabling calculation of LENT, PROMISE, mGPS and PICO scores, as well as a novel serum-based index (SIMPLE).<h4>Results</h4>678 patients were included in the cohort. LENT and PROMISE prognostic scoring models underperformed when compared with their serum-based counterparts. PROMISE showed the lowest area under the curve [AUC = 0.735 (95% CI 0.675-0.794)], followed by LENT [AUC = 0.758 (95% CI 0.710-0.808)], PICO [AUC = 0.781 (95% CI 0.725-0.837)] and mGPS [AUC = 0.819 (95% CI 0.745-0.893)]. The most significant serum-based factors (albumin, white blood cell counts and C-reactive protein) were selected for a new prognostic model. SIMPLE showed the highest numerical discriminatory performance [AUC = 0.852 (95% CI 0.782-0.921)], statistically outperforming MPE-specific scores, while demonstrating comparable discrimination to general oncology scores.<h4>Conclusion</h4>SIMPLE is a promising, accessible prognostic tool for patients with MPE, demonstrating strong discriminatory performance and outperforming LENT and PROMISE in our sample. External validation is required before routine clinical implementation.
Background
Accurate prognostication of malignant pleural effusion (MPE) is essential for guiding management decisions and providing survival estimates. Existing MPE-specific prognostic tools like LENT and PROMISE are recognized but have limited clinical uptake. This study introduces a novel serum-based index (SIMPLE) that may improve prognostic accuracy, which is critical in oncology.
Methods
This retrospective cohort study included patients diagnosed with MPE from 2012 to 2022 at a Portuguese tertiary hospital. Data were extracted from medical records to calculate LENT, PROMISE, mGPS, PICO scores, and the new SIMPLE index. The study focused on demographic, clinical, and biochemical data.
Results
The primary endpoint showed that SIMPLE had an AUC of 0.852 (95% CI 0.782-0.921), statistically outperforming LENT and PROMISE scores. The PROMISE score had an AUC of 0.735 (95% CI 0.675-0.794), while LENT had an AUC of 0.758 (95% CI 0.710-0.808). PICO and mGPS scores had AUCs of 0.781 (95% CI 0.725-0.837) and 0.819 (95% CI 0.745-0.893), respectively.
Interpretation
SIMPLE demonstrated a statistically significant improvement in prognostic discrimination compared to established MPE-specific scores. However, while the AUC of 0.852 indicates strong performance, the clinical significance of this improvement requires further investigation. Limitations include the need for external validation and potential biases inherent in retrospective studies.
Key findings
- 678 patients included in the cohort.
- PROMISE AUC = 0.735 (95% CI 0.675-0.794).
- LENT AUC = 0.758 (95% CI 0.710-0.808).
- PICO AUC = 0.781 (95% CI 0.725-0.837).
- mGPS AUC = 0.819 (95% CI 0.745-0.893).
- SIMPLE AUC = 0.852 (95% CI 0.782-0.921).
Limitations
- Retrospective cohort study design.
- External validation required.
- Single-site study.
- Potential biases from medical record data.